Sell-Off Picks Up With Some Biotechs Hit Hard
Smaller Cap Biotechs In Major Correction All the major indices are down in the 1.75% range and now the NASDAQ at 2902 is 100 pts. away from the elusive 3000 level. Analysts have been warning about a correction for weeks but with many indices up 10-15% YTD profit taking was inevitable. Driving...
Caution Rules: Easy Money Has Been Made With Biotech Up 15% YTD
Pause Mode Since February 15 The biotech indices and ETF's we track are off about 1% or more today as the market is in a profit taking mode. The Rayno Life Science Portfoio is also off about 1%. Speculative appetite is down with some MO stocks and former high-fliers taking a greater hit today:...
Biotech Bull Market Intact But Due For A Pause
Not A Good Time To Overweight Biotech Positions We are still in a holding pattern and recommend that caution be exercised regarding new positions. Although biotech stocks have made a nice run over the past five days driven by News from Vivus (VVUS) and Threshold (THLD) the IBB ($119.78) is...
Another Daily Reversal : Take More Off in Biotech
Have you read the book "Think Fast,Think Slow" by Daniel Kahneman? Well my System 1 (fast, intuitive and emotional) brain sees a lot of red on the screen telling me to take profits. If you want System 2 (slower, more deliberative, more logical) data to support this I can only offer the...
Gilead (GILD $46.50) off 15% on Hep-C Clinical Data -Viral Relapse Seen
$11B bet on Pharmasset acquisition for Hepatitus -C drug hits a snag Gilead announced that a majority (6/8) of the hepatitis C genotype-1 patients experienced a viral relapse when treated with GS-7977 Plus Ribavirin. Additional data will be forthcoming by the end of Q1 and Q2. Some analysts saw...